SoftOx Solutions AS works in a pan-European consortium to develop military
countermeasures against chemical substances, biological agents, radioactive
substances and nuclear material, so-called CBRN substances, for use in the
Norwegian Armed Forces and the EU's military forces.

In April 2021, SoftOx entered a three-year research collaboration with the
Norwegian Defence Research Establishment (FFI) to improve the operational
capability of Norwegian and international soldiers. In this connection, the
subsidiary SoftOx Defense Solutions AS (SDS) was established. Based on SoftOx
technology, SDS develops military applications for the Norwegian Armed Forces,
the EU's military forces, NATO and the US Armed Forces. The work with the
consortium lies in this company.

The consortium is led by France and the application is sent to the European
Defense Fund (EDF) on 9 December 2021. The research work is based on SoftOx's
technology as a basis for the development of military countermeasures and has a
total estimated total of approx. NOK 500 million (Euro 50 million). SDS's share
is estimated at approximately NOK 120 million (Euro 12 million) to develop a
military inhalation solution for the EU. The company will apply to EDF to cover
80 percent of the costs associated with the project, ie NOK approx. 96 million
(Euro 9.6 million). The Norwegian contribution must account for the rest, ie
approx. NOK 24 million (Euro 2.4 million)

The Ministry of Defense has decided to guarantee 40 percent of the Norwegian
contribution through so-called co-financing and has allocated SDS a total of
10.6 MNOK to the project.

- This is a sign of quality and a declaration of confidence from the Ministry of
Defence. We have big plans for SDS in the future, says CEO Geir Almås of SoftOx
Solutions.

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com